Back to search results

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Amyotrophic Lateral Sclerosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • St Joseph's Hospital and medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States

    Contact: Study coordinator (Dr S Ladha, Doctor of Medicine) · fulton.research@commonspirit.org · (602) 406-6262
    Contact: Principal Investigator (Dr Shafeeq Ladha, Doctor of Medicine)

  • University of California San Diego Medical Center, San Diego, California, United States

    Contact: Study coordinator (Dr John Ravits, Doctor of Medicine) · jravits@health.ucsd.edu · (858) 246-1154
    Contact: Principal Investigator (Dr John Ravits, Doctor of Medicine)

  • Mayo Clinic in Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Dr Bjorn Oskarsson, Doctor of Medicine) · oskarsson.bjorn@mayo.edu · (904) 953-0407
    Contact: Principal Investigator (Dr Bjorn Oskarsson, Doctor of Medicine)

  • University of Miami School of Science, Miami, Florida, United States

    Contact: Study coordinator (Dr Michael Benatar, Doctor of Medicine) · mbenatar@med.miami.edu · (305) 243-6480
    Contact: Principal Investigator (Dr Michael Benatar, Doctor of Medicine)

  • Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Winifred Asigri Study Coordinator) · pioneeralshealey@mgb.org · (617) 724-5659
    Contact: Principal Investigator (Dr Doreen Ho, Doctor of Medicine)

  • Herbert Irving Comprehensive Cancer Center, New York, New York, United States

    Contact: Study coordinator (Dr Neil Schneider, Doctor of Medicine) · ns327@columbia.edu · (212) 342-3107
    Contact: Principal Investigator (Dr Neil Schneider, Doctor of Medicine)

  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Spriha Thapa Study Coordinator) · Spriha.Thapa@pennmedicine.upenn.edu · 267-610-8822
    Contact: Principal Investigator (Dr Colin Quinn, Doctor of Medicine)

  • UZ Leuven, Leuven, Belgium

    Contact: Study coordinator (Evi Parente Study Coordinator) · evi.parente@uzleuven.be · + 32 1638668
    Contact: Study coordinator (Ann Dhondt Study Coordinator) · ann.dhondt@uzleuven.be · + 32 16347577
    Contact: Principal Investigator (Dr Philip Van Damme, Doctor of Medicine)

  • UMC Utrecht, Utrecht, Netherlands

    Contact: Study coordinator (Prof Leonard Van Den Berg, Doctor of Medicine) · l.h.vandenberg@umcutrecht.nl · +31 887555555
    Contact: Principal Investigator (Prof Leonard Van Den Berg, Doctor of Medicine)

  • Kings College Hospital, London, United Kingdom

    Contact: Study coordinator (Dr Ammar Al-Chalabi, Doctor of Medicine) · ammar.al-chalabi@kcl.ac.uk · +44 2032991778

  • Royal Hallamshire Hospital, Sheffield, United Kingdom

    Contact: Study coordinator (Dr Chris McDermott, Doctor of medicine) · +44 114 226 1049
View source on ClinicalTrials.gov(opens in a new tab)